{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:13:47Z","timestamp":1793978027772,"version":"4.8.0"},"reference-count":49,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Research Foundation and the University Hospital Essen","award":["FU 356\/12-2"],"award-info":[{"award-number":["FU 356\/12-2"]}]},{"name":"Open Access Publication Fund of the University of Duisburg-Essen","award":["FU 356\/12-2"],"award-info":[{"award-number":["FU 356\/12-2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: To clarify the therapy response in orbital inflammatory diseases (OID), we analyzed the treatment effects of steroid therapy, the use of disease-modifying antirheumatic drugs (DMARDS), and biologicals in our tertiary referral center cohort. Methods: We collected the clinical and demographic data of all patients treated for non-specific orbital inflammation (NSOI) (n = 111) and IgG4-ROD (n = 13), respectively at our center from 2008 to 2020 and analyzed them with descriptive statistics. NSOI were sub-grouped according to the location into either idiopathic dacryoadenitis (DAs) (n = 78) or typical idiopathic orbital myositis (n = 32). Results: Mean age at first clinical manifestation was significantly different between subgroups (IOI: 49.5 \u00b1 18, IgG4-ROD: 63.2 \u00b1 14, p = 0.0171). Among all examined OID, 63 patients (50%) achieved full remission (FR) with corticosteroids (NSOI 53%\/IgG4-ROD 31%). In contrast, classic myositis showed a significantly higher response (76%). Disease-modifying drugs (DMARDS) for myositis accomplished only 33% FR (NSOI 57%) and 66% did not respond sufficiently (NSOI 43%). The biologic agent (Rituximab) was significantly more efficient: 19 of 23 patients (82%) achieved full remission and only 4 (17%) did not respond fully and needed orbital irradiation or orbital decompressive surgery.<\/jats:p>","DOI":"10.3390\/jcm13143998","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T11:17:09Z","timestamp":1720523829000},"page":"3998","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment Outcomes of Patients with Orbital Inflammatory Diseases: Should Steroids Still Be the First Choice?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5874-764X","authenticated-orcid":false,"given":"Karim","family":"Al-Ghazzawi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Neumann","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareile","family":"Knetsch","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wilde","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0180-1112","authenticated-orcid":false,"given":"Nikolaos E.","family":"Bechrakis","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Eckstein","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oeverhaus","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100885","DOI":"10.1016\/j.preteyeres.2020.100885","article-title":"Non-specific orbital inflammation: Current understanding and unmet needs","volume":"81","author":"Lee","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-0420.1996.tb00069.x","article-title":"Idiopathic orbital inflammatory disease","volume":"74","author":"Gunalp","year":"1996","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/bjo.2007.124156","article-title":"Idiopathic orbital inflammatory syndrome: Clinical features and treatment outcomes","volume":"91","author":"Swamy","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.semarthrit.2013.11.008","article-title":"Ophthalmic manifestations of IgG4-related disease: Single-center experience and literature review","volume":"43","author":"Wallace","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.iop.0000203734.52333.93","article-title":"Idiopathic orbital inflammation: A pathogenetic construct and treatment strategy: The 2005 ASOPRS Foundation Lecture","volume":"22","author":"Harris","year":"2006","journal-title":"Ophthalmic Plast Reconstr. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s00347-021-01348-x","article-title":"Specific inflammations of the orbit","volume":"118","author":"Klingenstein","year":"2021","journal-title":"Ophthalmologe"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Al-Ghazzawi, K., Mairinger, F.D., Pfortner, R., Horstmann, M., Bechrakis, N., Mohr, C., Eckstein, A., and Oeverhaus, M. (2022). Novel Insights into Pathophysiology of Orbital Inflammatory Diseases and Progression to Orbital Lymphoma by Pathway Enrichment Analysis. Life, 12.","DOI":"10.3390\/life12101660"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3928\/01913913-20190923-02","article-title":"Idiopathic Orbital Pseudotumor Preceding Systemic Inflammatory Disease in Children","volume":"56","author":"Tsukikawa","year":"2019","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00055735-200212000-00001","article-title":"Diagnosis and management of orbital pseudotumor","volume":"13","author":"Jacobs","year":"2002","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Al-Ghazzawi, K., Baum, S.H., Pfortner, R., Philipp, S., Bechrakis, N., Gortz, G., Eckstein, A., Mairinger, F.D., and Oeverhaus, M. (2022). Evaluation of Orbital Lymphoproliferative and Inflammatory Disorders by Gene Expression Analysis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158609"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1007\/s00330-022-08857-6","article-title":"A deep learning model combining multimodal radiomics, clinical and imaging features for differentiating ocular adnexal lymphoma from idiopathic orbital inflammation","volume":"32","author":"Xie","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.semarthrit.2007.06.003","article-title":"Orbital inflammatory disease","volume":"37","author":"Lutt","year":"2008","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41433-020-1083-x","article-title":"Clinical features and outcomes of IgG4-related idiopathic orbital inflammatory disease: From a large southern China-based cohort","volume":"35","author":"Chen","year":"2021","journal-title":"Eye"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jamaophthalmol.2013.8179","article-title":"Rituximab therapy for refractory orbital inflammation: Results of a phase 1\/2, dose-ranging, randomized clinical trial","volume":"132","author":"Suhler","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/bjo.2007.133173","article-title":"Rituximab for treatment of ocular inflammatory disease: A series of four cases","volume":"93","author":"Kurz","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3109\/09273948.2013.863943","article-title":"Complete resolution of idiopathic sclerosing orbital inflammation after treatment with rituximab","volume":"23","author":"Abell","year":"2015","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wu, K.Y., Kulbay, M., Daigle, P., Nguyen, B.H., and Tran, S.D. (2024). Nonspecific Orbital Inflammation (NSOI): Unraveling the Molecular Pathogenesis, Diagnostic Modalities, and Therapeutic Interventions. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031553"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/meajo.MEAJO_44_18","article-title":"Idiopathic Orbital Inflammation: Review of Literature and New Advances","volume":"25","author":"Yesiltas","year":"2018","journal-title":"Middle East. Afr. J. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Aryasit, O., Tiraset, N., Preechawai, P., Kayasut, K., Sanghan, N., and Sittivarakul, W. (2021). IgG4-related disease in patients with idiopathic orbital inflammation. BMC Ophthalmol., 21.","DOI":"10.1186\/s12886-021-02115-x"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/bjophthalmol-2018-313730","article-title":"Long-term outcomes of ocular adnexal lesions in IgG4-related ophthalmic disease","volume":"104","author":"Kubota","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/aos.14048","article-title":"The treatment outcomes in IgG4-related orbital disease: A systematic review of the literature","volume":"97","author":"Detiger","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12348-021-00253-3","article-title":"Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease","volume":"11","author":"Ng","year":"2021","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/01676830.2021.1874424","article-title":"Long-term follow up of systemic rituximab therapy as first-line and salvage therapy for idiopathic orbital inflammation and review of the literature","volume":"41","author":"Thangavel","year":"2022","journal-title":"Orbit"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ajo.2005.04.053","article-title":"Successful treatment of idiopathic orbital inflammation with mycophenolate mofetil","volume":"140","author":"Hatton","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ophtha.2015.01.016","article-title":"Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease","volume":"122","author":"Joshi","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","article-title":"The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD","volume":"31","author":"Umehara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ajo.2004.06.077","article-title":"Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab","volume":"138","author":"Garrity","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/SCS.0000000000000510","article-title":"Idiopathic orbital myositis","volume":"25","author":"Yan","year":"2014","journal-title":"J. Craniofac Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0161-6420(96)30663-5","article-title":"Are systemic corticosteroids useful in the management of orbital pseudotumors?","volume":"103","author":"Mombaerts","year":"1996","journal-title":"Ophthalmology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/ICU.0b013e328355715e","article-title":"Inflammatory modulators and biologic agents in the treatment of idiopathic orbital inflammation","volume":"23","author":"Carruth","year":"2012","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2710.2000.00284.x","article-title":"Is enough attention being given to the adverse effects of corticosteroid therapy?","volume":"25","author":"Hougardy","year":"2000","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0161-6420(91)32064-5","article-title":"Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy","volume":"98","author":"Bielory","year":"1991","journal-title":"Ophthalmology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11926-010-0128-8","article-title":"Orbital inflammatory pseudotumors: Etiology, differential diagnosis, and management","volume":"12","author":"Espinoza","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0936-6555(05)80017-2","article-title":"Cyclophosphamide induced remission in relapsed, progressive idiopathic orbital inflammation (\u2018Pseudotumour\u2019)","volume":"7","author":"Eagle","year":"1995","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/bjo.85.10.1220","article-title":"A role for methotrexate in the management of non-infectious orbital inflammatory disease","volume":"85","author":"Smith","year":"2001","journal-title":"Br. J. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10067-008-1040-8","article-title":"Idiopathic orbital inflammatory disease successfully treated with rituximab","volume":"28","author":"Schafranski","year":"2009","journal-title":"Clin. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ashkenazy, N., Saboo, U.S., Abraham, A., Ronconi, C., and Cao, J.H. (2019). Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis. J. AAPOS, 23.","DOI":"10.1016\/j.jaapos.2019.02.006"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/07357907.2018.1489550","article-title":"Radiotherapy for Orbital Pseudotumor: The University of Florida Experience","volume":"36","author":"Mokhtech","year":"2018","journal-title":"Cancer Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijrobp.2011.11.031","article-title":"Radiotherapy with or without surgery for patients with idiopathic sclerosing orbital inflammation refractory or intolerant to steroid therapy","volume":"84","author":"Lee","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/03009742.2015.1055796","article-title":"IgG4-related disease in Italy: Clinical features and outcomes of a large cohort of patients","volume":"45","author":"Campochiaro","year":"2016","journal-title":"Scand. J. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/gutjnl-2012-302886","article-title":"Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The Mayo Clinic experience","volume":"62","author":"Hart","year":"2013","journal-title":"Gut"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0161-6420(97)30300-5","article-title":"Outcome of orbital myositis: Clinical features associated with recurrence","volume":"104","author":"Mannor","year":"1997","journal-title":"Ophthalmology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jfo.2012.09.012","article-title":"Pr\u00e9sentation clinique et prise en charge des myosites aigu\u00ebs dans les inflammations orbitaires non sp\u00e9cifiques [Clinical features and management of acute myositis in idiopathic orbital inflammation]","volume":"36","author":"Halimi","year":"2013","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00415-015-7926-x","article-title":"Orbiting around the orbital myositis: Clinical features, differential diagnosis and therapy","volume":"263","author":"Montagnese","year":"2016","journal-title":"J. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kang, M.S., Yang, H.K., Kim, N., and Hwang, J.-M. (2020). Clinical Features of Ocular Motility in Idiopathic Orbital Myositis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041165"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2015.11.032","article-title":"Idiopathic Dacryoadenitis: Clinical Features, Histopathology, and Treatment Outcomes","volume":"163","author":"Andrew","year":"2016","journal-title":"Am. Jounral Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e001005","DOI":"10.1136\/bmjophth-2022-001005","article-title":"Clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation","volume":"7","author":"Kubota","year":"2022","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/archopht.121.4.491","article-title":"Idiopathic Orbital Inflammation: Distribution, Clinical Features, and Treatment Outcome","volume":"121","author":"Yuen","year":"2003","journal-title":"Arch. Ophthalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/14\/3998\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:12:07Z","timestamp":1760109127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/14\/3998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":49,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcm13143998"],"URL":"https:\/\/doi.org\/10.3390\/jcm13143998","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]}}}